Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells

Experimental Eye Research

Volumn 91, Issue 1, 2010, Pages 34-41

  Yanni, Susan E ^a   McCollum, Gary W ^a   Penn, John S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; COX 2; Hypoxia; M ller cells; Prostanoids; VEGF

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HYPOXIA; MASS FRAGMENTOGRAPHY; MOUSE; MUELLER CELL; MUTATIONAL ANALYSIS; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENE DELETION; ISOQUINOLINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; PROSTAGLANDINS; PROTEIN KINASE INHIBITORS; RETINAL NEURONS; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953361126     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2010.03.019     Document Type: Article

References (61)

1. Abdel-Majid R.M., Marshall J.S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J. Immunol. 2004, 172:1227-1236.
2. Abdelrahim M., Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol. 2005, 68:317-329.
3. Aiello L.P., Northrup J.M., Keyt B.A., Takagi H., Iwamoto M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalomol. 1995, 113:1538-1544.
4. Aiello L.P. Vascular endothelial growth factor: 20th-century mechanisms, 21st-century therapies. Invest. Ophthalmol. Vis. Sci. 1997, 38:1647-1652.
5. Amano H., Ando K., Minamida S., Hayashi I., Ogino M., Yamashina S., Yoshimura H., Majima M. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn. J. Pharmacol. 2001, 87:181-188.
6. Amano H., Haysahi I., Yoshida S., Yoshimura H., Majima M. Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Hum. Cell. 2002, 15:13-24.
7. Amrite A.C., Ayalasomayajula S.P., Cheruvu N.P.S., Kompella U.B. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 2006, 47:1149-1160.
8. Ayalasomayajula S.P., Kompella U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 2003, 458:283-289.
9. Ayalasomayajula S.P., Amrite A.C., Kompella U.B. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur. J. Pharmacol. 2004, 498:275-278.
10. Bai Y., Ma J.X., Guo J., Wang J., Zhu M., Chen Y., Le Y.Z. Müller cell-derived VEGF is significant contributor to retinal neovascularization. J. Pathol. 2009, 219:446-454.
11. Bonazzi A., Mastyugin V., Mieyal P.A., Dunn M.W. Laniado-Schwartzman M. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J. Biol. Chem. 2000, 275:2837-2844.
12. Bradbury D., Clarke D., Seedhouse C., Corbett L., Stocks J., Knox A. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J. Biol. Chem. 2005, 280:29993-30000.
13. Casey R., Li W.W. Factors controlling ocular angiogenesis. Am. J. Ophthalmol. 1997, 124:521-529.
14. Castro M.R., Lutz D., Edelman J.L. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp. Eye Res. 2004, 79:275-285.
15. Cheng T., Cao W., Wen R., Steinberg R.H., LaVail M.M. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest. Ophthalmol. Vis. Sci. 1998, 39:581-591.
16. Cryan L.M., Pidgeon G.P., Fitzgerald D.J., O'Brien C.J. COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy. Mol. Vis. 2006, 12:405-414.
17. Csiki I., Yanagisawa K., Haruki N., Nadaf S., Morrow J.D., Johnson D.H., Carbone D.P. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1 in non-small cell lung cancer. Cancer Res. 2006, 66:143-150.
18. D'Amore P.A. Mechanisms of retinal and choroidal angiogenesis. Invest. Ophthalmol. Vis. Sci. 1994, 35:3974-3979.
19. Damm J., Rau T., Maihofner C., Pahl A., Brune K. Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body. Exp. Eye Res. 2001, 72:611-621.
20. Demasi M., Cleland L.G., Cook-Johnson R.J., Caughey G.E., James M.J. Effects of hypoxia on monocyte inflammatory mediator production: dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. J. Biol. Chem. 2003, 278:38607-38616.
21. Demasi M., Cleland L.G., Cook-Johnson R.J., James M.J. Effects of hypoxia on the expression and activity of cyclooxygenase 2 in fibroblast-like synoviocytes: interactions with monocyte-derived soluble mediators. Arthritis Rheum. 2004, 50:2441-2449.
22. DuBois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., Lipsky P.E. Cyclooxygenase in biology and disease. FASEB J. 1998, 12:1063-1073.
23. Eibl G., Bruemmer D., Okada Y., Duffy J.P., Law R.E., Reber H.A., Hines O.J. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2003, 306:887-897.
24. Ershov A.V., Bazan N.G. Induction of cyclooxygenase-2 gene expression in retinal pigment epithelium cells by photoreceptor rod outer segment phagocytosis and growth factors. J. Neurosci. Res. 1999, 58:254-261.
25. Form D.M., Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 1983, 172:214-218.
26. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., Chiarugi V., Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001, 3:53-61.
27. Hata A.N., Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 2004, 103:147-166.
28. Hatazawa R., Tanigami M., Izumi N., Kamei K., Tanaka A., Takeuchi K. Prostaglandin E2 stimulates VEGF expression in primary rat gastric fibroblasts through EP4 receptors. Inflammopharmacology 2007, 15:214-217.
29. Hicks D., Curtois Y. The growth and behaviour of rat retinal Müller cells in vitro. 1. An improved method for isolation and culture. Exp. Eye Res. 1990, 51:119-129.
30. Hla T., Bishop-Bailey D., Liu C.H., Schaefers H.J., Trifan O.C. Cyclooxygenase-1 and -2 isoenzymes. Int. J. Biochem. Cell Biol. 1999, 31:551-557.
31. Höper M.M., Voelkel N.F., Bates T.O., Allard J.D., Horan M., Shepherd D., Tuder R.M. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am. J. Respir. Cell Mol. Biol. 1997, 17:748-756.
32. Hu W., Criswell M.H., Ottlecz A., Cornell T.L., Danis R.P., Lambrou G.N., Ciulla T.A. Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina 2005, 25:1054-1064.
33. Ju W.-K., Neufeld A.H. Cellular localization of cyclooxygenase-1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J. Comp. Neurol. 2002, 452:392-399.
34. Kaida A., Qualtrough D., Williams A.C., Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006, 66:6683-6691.
35. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58:409-412.
36. Kuzmanovic M., Dudley V.J., Sarthy V.P. GFAP promoter drives Müller cell-specific expression in transgenic mice. Invest. Ophthalmol. Vis. Sci. 2003, 44:3606-3613.
37. Lee P., Wang C.C., Adamis A.P. Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol. 1998, 43:245-269.
38. Maihofner C., Schlotzer-Schrehardt U., Guhring H., Zeilhofer H.U., Naumann G.O., Pahl A., Mardin C., Tamm E.R., Brune K. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest. Ophthalmol. Vis. Sci. 2001, 42:2616-2624.
39. Monnin J., Morand-Villeneuve N., Michel G., Hicks D., Versaux-Botteri C. Production of neurospheres from mammalian Müller cells in culture. Neurosci. Lett. 2007, 421:22-26.
40. Pai R., Szabo I.L., Soreghan B.A., Atay S., Kawanaka H., Tarnawski A.S. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 2001, 286:923-928.
41. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., Smith L.E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA 1995, 92:905-909.
42. Rahmani B., Tielsch J.M., Kat J., Gottsch J., Quigley H., Javitt J., Sommer A. The cause-specific prevalence of visual impairment in an urban population. The Baltimore eye survey. Ophthalmology 1999, 103:1721-1726.
43. Regan J.W. EP2 and EP4 prostanoid receptor signaling. Life Sci. 2003, 74:143-153.
44. Robbins S.G., Conaway J.R., Ford B.L., Roberto K.A., Penn J.S. Detection of VEGF protein in vascular and non-vascular cells of the normal and oxygen-injured retina. Growth Factor. 1997, 14:229-241.
45. Robbins S.G., Rajaratnam V.S., Penn J.S. Evidence for upregulation of vascular endothelial cell growth factor by hypoxia. Growth Factor. 1998, 16:1-9.
46. Schmedtje J.F., Ji Y.S., Liu W.L., DuBois R.N., Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappa B p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 1997, 272:601-608.
47. Sennlaub F., Valamanesh F., Vazquez-Tello A., El-Asrar A.M., Checchin D., Brault S., Gobeil F., Beauchamp M.H., Mwaikambo B., Curtois Y., Geboes K., Varma D.R., Lachapelle P., Ong H., Behar-Cohen F., Chemtob S. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003, 108:198-204.
48. Steinkuller P.G., Du L., Gilbert C., Foster A., Collins M.L., Coats D.K. Childhood blindness. J. AAPOS 1999, 3:26-32.
49. Takahashi H., Yanagi Y., Tamaki Y., Uchida S., Muranaka K. COX-2-selective inhibitor, etodolac, suppresses neovascularization in a mice model. Biochem. Biophys. Res. Commun. 2004, 325:461-466.
50. Takahashi K., Saishin Y., Saishin Y., Mori K., Ando A., Yamamoto S., Oshima Y., Nambu H., Melia M.B., Bingaman D.P., Campochiaro P.A. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 2003, 44:409-415.
51. Wang D., DuBois R.N. Cycooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc. Natl. Acad. Sci. USA 2004, 101:415-416.
52. Wang M.T., Honn K.V., Nie D. Cyclooxygenases, prostanoids, and tumor progress, ion. Cancer Metastasis Rev. 2007, 26:525-534.
53. Wang X., Klein R.D. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol. Carcinog. 2007, 46:912-923.
54. Werdich X.Q., Penn J.S. Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2006, 47:5047-5056.
55. Wilkinson-Berka J.L., Alousis N.S., Kelly D.J. Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2003, 44:974-979.
56. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999, 18:7908-7916.
57. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 2000, 105:1589-1594.
58. Yamada M., Kawai M., Kawai Y., Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye Res. 1999, 19:300-304.
59. Yanni S.E., Barnett J.M., Clark M.L., Penn J.S. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest. Ophthalmol. Vis. Sci. 2009, 50:5479-5486.
60. Yanni S.E., Clark M.L., Yang R., Bingaman D.P., Penn J.S. The effects of nepafenac and Amfenac on retinal angiogenesis. Brain Res. Bull. 2010, 81:310-319.
61. Ziche M., Jones J., Gullino P.M. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 1982, 69:475-482.